Lymphocytic vasculitis in X-linked lymphoproliferative disease.
暂无分享,去创建一个
D. Demetrick | A. Junker | R. Tan | J. Dutz | J P Dutz | L Benoit | X Wang | D J Demetrick | A Junker | D de Sa | R Tan | Xiaoxia Wang | X. Wang | R. Tan | D. de Sa | L. Benoît | Derek de Sa
[1] M. Bennett,et al. Cloning and characterization of the 2B4 gene encoding a molecule associated with non-MHC-restricted killing mediated by activated natural killer cells and T cells. , 1993, Journal of immunology.
[2] S R Goldstein,et al. Laser capture microdissection of single cells from complex tissues. , 1999, BioTechniques.
[3] D. Purtilo,et al. Deficient natural killer cell activity in x-linked lymphoproliferative syndrome. , 1980, Science.
[4] D. Baltimore,et al. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo , 1992, Molecular and cellular biology.
[5] M. Dillon,et al. Childhood vasculitis , 1998, Lupus.
[6] P. Lai,et al. Defective control of Epstein‐Barr virus‐infected B cell growth in patients with X‐linked lymphoproliferative disease , 1991, Clinical and experimental immunology.
[7] R. Petty,et al. A syndrome of childhood polyarteritis. , 1977, The Journal of pediatrics.
[8] D. Hayoz,et al. SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients , 1999, Human Genetics.
[9] H. Pabst,et al. Cutting Edge: Defective NK Cell Activation in X-Linked Lymphoproliferative Disease1 , 2000, The Journal of Immunology.
[10] I. Ernberg,et al. Cellular immune defects to Epstein-Barr virus-determined antigens in young males. , 1981, Cancer research.
[11] Y. Ench,et al. Characterization of natural Epstein‐Barr virus infection and replication in smooth muscle cells from a leiomyosarcoma , 1999, Journal of medical virology.
[12] S. Tangye,et al. Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. , 1999, Journal of immunology.
[13] E. Snyder,et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[14] Jack R. Davis,et al. X-Linked Lymphoproliferative Disease: Twenty-Five Years after the Discovery , 1995, Pediatric Research.
[15] D. Purtilo,et al. Cell‐mediated immunity to Epstein‐Barr virus (EBV) and natural killer (NK)‐cell activity in the X‐linked lymphoproliferative syndrome , 1982, International journal of cancer.
[16] H. Ochs,et al. Necrotizing lymphoid vasculitis in X-linked lymphoproliferative syndrome. , 1985, Archives of pathology & laboratory medicine.
[17] A. Rickinson. Epstein-Barr virus. , 2001, Virus research.
[18] U. Nater,et al. Epstein-Barr virus. , 1991, The Journal of family practice.
[19] G. Vawter,et al. X-LINKED RECESSIVE PROGRESSIVE COMBINED VARIABLE IMMUNODEFICIENCY (DUNCAN'S DISEASE) , 1975, The Lancet.
[20] C Terhorst,et al. Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition. , 1999, Molecular cell.
[21] D. Moss,et al. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.
[22] K. Hayashi,et al. Chronic active Epstein-Barr virus infection with giant coronary aneurysms. , 1996, American journal of clinical pathology.
[23] L. Guillevin,et al. Polyarteritis nodosa, microscopic polyangiitis and Churg–Strauss syndrome , 1998, Lupus.
[24] Jack R. Davis,et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene , 1998, Nature Genetics.
[25] D. Allen,et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM , 1998, Nature.
[26] S. Argov,et al. Defective natural killing activity but retention of lymphocyte-mediated antibody-dependent cellular cytotoxicity in patients with the X-linked lymphoproliferative syndrome. , 1986, Cellular immunology.
[27] Jack R. Davis,et al. The X-linked lymphoproliferative disease: from autopsy toward cloning the gene 1975-1990. , 1991, Pediatric pathology.
[28] B. Cocks,et al. Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production. , 1997, Journal of immunology.
[29] H. Grossniklaus,et al. Retinal necrosis in X-linked lymphoproliferative disease. , 1994, Ophthalmology.
[30] B. Griffin,et al. Clustered repeat sequences in the genome of Epstein Barr virus. , 1983, Nucleic acids research.
[31] J. Saffitz,et al. Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. , 1997, Nature medicine.
[32] K. Aozasa,et al. Large-vessel arteritis associated with chronic active Epstein-Barr virus infection. , 1998, Arthritis and rheumatism.
[33] H. Takeuchi,et al. Systemic granulomatous arteritis associated with Epstein-Barr virus infection , 1999, Virchows Archiv.
[34] W. Crist,et al. Fatal Epstein-Barr virus-associated hemophagocytic syndrome. , 1981, The Journal of pediatrics.
[35] A. Purohit,et al. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. , 1993, Journal of immunology.